Bio-Rad Laboratories, Inc. (BIO) Shares Bought by MERIAN GLOBAL INVESTORS UK Ltd

MERIAN GLOBAL INVESTORS UK Ltd raised its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1,194.9% during the first quarter, Holdings Channel reports. The fund owned 24,603 shares of the medical research company’s stock after buying an additional 22,703 shares during the quarter. MERIAN GLOBAL INVESTORS UK Ltd’s holdings in Bio-Rad Laboratories were worth $7,520,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of BIO. Quadrant Capital Group LLC raised its holdings in shares of Bio-Rad Laboratories by 205.9% in the 1st quarter. Quadrant Capital Group LLC now owns 104 shares of the medical research company’s stock worth $29,000 after acquiring an additional 70 shares during the last quarter. Financial Gravity Wealth Inc. acquired a new stake in shares of Bio-Rad Laboratories in the 1st quarter worth about $57,000. Enlightenment Research LLC acquired a new stake in shares of Bio-Rad Laboratories in the 4th quarter worth about $70,000. Osborn Williams & Donohoe LLC acquired a new stake in shares of Bio-Rad Laboratories in the 1st quarter worth about $98,000. Finally, Private Capital Group LLC raised its holdings in shares of Bio-Rad Laboratories by 254.5% in the 1st quarter. Private Capital Group LLC now owns 390 shares of the medical research company’s stock worth $119,000 after acquiring an additional 280 shares during the last quarter. 64.30% of the stock is currently owned by institutional investors and hedge funds.

NYSE:BIO opened at $296.72 on Friday. The company has a quick ratio of 3.24, a current ratio of 4.57 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $8.84 billion, a price-to-earnings ratio of 50.81, a PEG ratio of 2.77 and a beta of 1.23. Bio-Rad Laboratories, Inc. has a 52 week low of $220.05 and a 52 week high of $345.15.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, May 8th. The medical research company reported $1.65 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.12 by $0.53. The firm had revenue of $553.98 million during the quarter, compared to analyst estimates of $548.82 million. Bio-Rad Laboratories had a net margin of 24.84% and a return on equity of 4.15%. Equities analysts forecast that Bio-Rad Laboratories, Inc. will post 7.15 earnings per share for the current year.

A number of research firms recently weighed in on BIO. ValuEngine upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, May 9th. Barclays upped their target price on shares of Bio-Rad Laboratories from $340.00 to $350.00 and gave the stock an “overweight” rating in a report on Thursday, May 9th. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “strong-buy” rating and set a $360.00 target price on the stock in a report on Wednesday, March 6th. Finally, Deutsche Bank upped their target price on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a report on Thursday, May 9th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Bio-Rad Laboratories currently has a consensus rating of “Buy” and a consensus price target of $365.00.

In other Bio-Rad Laboratories news, EVP Timothy S. Ernst sold 345 shares of the stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $290.00, for a total value of $100,050.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 27.84% of the company’s stock.

WARNING: This report was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://sportsperspectives.com/2019/05/19/bio-rad-laboratories-inc-bio-shares-bought-by-merian-global-investors-uk-ltd.html.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

See Also: Diversification Important in Investing

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.